2X Blend – CJC-1295 (No DAC) (5 mg) / Ipamorelin (5 mg)

GHRH Analog + GHRP Agonist / Growth Hormone Pulse Modulator / IGF-1 Pathway Research Peptide Blend

2X Blend combines CJC-1295 (Without DAC) and Ipamorelin in a dual-mechanism research formulation designed to stimulate endogenous growth hormone release through complementary signaling pathways.

CJC-1295 (No DAC) functions as a growth hormone–releasing hormone (GHRH) analog, while Ipamorelin acts as a selective growth hormone secretagogue receptor (GHS-R1a) agonist. Together, this blend is widely studied for its ability to enhance pulsatile growth hormone secretion while maintaining physiological signaling patterns.

This combination supports research involving anabolic signaling, IGF-1 modulation, tissue repair modeling, recovery pathways, and metabolic regulation studies.

RESEARCH

CJC-1295 (Without DAC) is a synthetic analog of endogenous GHRH designed to increase amplitude and frequency of natural growth hormone pulses without extended half-life modification.

Ipamorelin is a selective pentapeptide GHRP that stimulates GH release via ghrelin receptor activation with minimal influence on cortisol or prolactin pathways in experimental models.

When combined, these compounds are studied for their synergistic activation of pituitary somatotroph cells through dual receptor pathways:

• GHRH receptor activation (CJC-1295 No DAC)
• Ghrelin receptor (GHS-R1a) activation (Ipamorelin)

The 2X Blend is provided in lyophilized powder form for controlled in vitro research applications involving growth factor signaling, endocrine modeling, metabolic analysis, and regenerative pathway studies.

Chemical Information:

CJC-1295 (Without DAC)

Molecular Formula: C152H252N44O42
Molecular Weight: ~3367.9 g/mol
Structure: Modified GHRH(1–29) analog

Ipamorelin

Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 g/mol
Structure: Pentapeptide growth hormone secretagogue

Blend Composition:

• 5 mg CJC-1295 (Without DAC)
• 5 mg Ipamorelin
• Total peptide content: 10 mg per vial

Description:

2X Blend (CJC-1295 No DAC / Ipamorelin) is a synthetic peptide combination supplied exclusively for qualified laboratory research.

This product is intended solely for non-clinical, in vitro experimental studies under controlled laboratory conditions.

The material is provided in lyophilized powder form for structural, biochemical, and receptor-binding analysis involving growth hormone secretion and IGF-1 pathway modeling.

No claims regarding biological activity, therapeutic effects, or clinical applications are made or implied.

Research Applications:

Growth Hormone Pulse Amplification Studies

• Investigate dual-receptor stimulation of endogenous GH secretion.

IGF-1 Pathway Modeling

• Examine downstream anabolic signaling and tissue repair mechanisms.

Muscle & Connective Tissue Research

• Study protein synthesis, collagen formation, and cellular regeneration models.

Metabolic Regulation Analysis

• Explore lipid metabolism, glucose balance, and energy pathway modulation.

Endocrine System Feedback Studies

• Assess hypothalamic–pituitary axis dynamics and hormonal rhythm coordination.

Storage and Handling:

• Store lyophilized powder at −20°C
• Once reconstituted, store at 2–8°C and use promptly
• Maintain aseptic laboratory technique during handling

Product Specifications:

Purity: ≥99% (HPLC Certified)
Appearance: Lyophilized white powder
Solubility: Soluble in bacteriostatic water
Form: 10 mg total peptide blend (5 mg / 5 mg) per vial

Compliance Notice:

2X Blend (CJC-1295 Without DAC / Ipamorelin) is FOR RESEARCH USE ONLY.
It is not intended for human or veterinary use.
This product has not been evaluated by the FDA.
Improper use may violate federal, state, or local laws.

By purchasing this product, the buyer represents and warrants that it will be used solely for in vitro scientific research.

Key Research Features:

• Dual-pathway stimulation of growth hormone secretion
• Combines GHRH analog with selective GHS-R1a agonist
• Supports physiologic pulsatile GH release modeling
• Enhances IGF-1 pathway activation in experimental systems
• Minimal reported cortisol or prolactin elevation in selective receptor studies
• Frequently examined in combination with Tesamorelin, HGH (191AA), and IGF-1 research frameworks

Mechanism of Action (Simplified):

1. CJC-1295 (No DAC) binds GHRH receptors
   → increases amplitude of GH pulse secretion
2. Ipamorelin activates ghrelin (GHS-R1a) receptors
   → stimulates additional GH release without broad endocrine activation
3. Dual receptor synergy
   → enhances natural pulsatile GH output
4. Increased circulating IGF-1 (experimental models)
   → supports anabolic and regenerative signaling
5. Supports tissue-repair and metabolic pathway modeling
   → useful for studies on muscle growth, recovery, and fat metabolism

Applications / Possible Uses:

• Growth hormone secretagogue research
• IGF-1 pathway and anabolic signaling studies
• Muscle regeneration and recovery modeling
• Fat metabolism and metabolic pathway analysis
• Endocrine rhythm and pituitary function research
• Often studied alongside HGH (191AA), Tesamorelin, or IGF-1 LR3

Form / Notes:

• Lyophilized vial for reconstitution
• Balanced 1:1 blend (5 mg / 5 mg)
• Designed for dual-pathway GH stimulation research
• Suitable for endocrine and regenerative laboratory models